XML 103 R54.htm IDEA: XBRL DOCUMENT v3.3.1.900
Acquisitions, Licensing Agreements, Collaborative Arrangements, Divestitures, Equity-Method Investments and Cost-Method Investment - Equity and Cost-Method Investments (Details) - USD ($)
$ in Millions
1 Months Ended 3 Months Ended 12 Months Ended
Apr. 30, 2015
Sep. 27, 2015
Mar. 31, 2013
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Apr. 01, 2014
Oct. 01, 2013
Sep. 30, 2013
Oct. 31, 2012
Oct. 30, 2012
Sep. 06, 2012
Schedule of Equity Method Investments [Line Items]                        
Gain associated with the transfer of certain product rights to an equity-method investment [1],[2]       $ 0.0 $ 0.0 $ 459.0            
Finite-lived intangible asset, useful life       11 years                
Hisun Pfizer Pharmaceuticals Co. Ltd [Member]                        
Schedule of Equity Method Investments [Line Items]                        
Equity method investment, registered capital                       $ 250.0
Equity method investments       $ 775.0 1,400.0             $ 122.5
Equity method investment, ownership percentage       49.00%               49.00%
Gain associated with the transfer of certain product rights to an equity-method investment     $ 459.0                  
Gain (loss) associated with indirect retained interest     $ 225.0                  
Equity method investment, underlying equity in net assets       $ 668.0 780.0              
Finite-lived intangible asset, useful life       25 years                
Hisun Pfizer Pharmaceuticals Co. Ltd [Member] | Other Nonoperating Income (Expense) [Member]                        
Schedule of Equity Method Investments [Line Items]                        
Equity method investment, recognized gain (loss)   $ (463.0)                    
ViiV Healthcare Limited [Member]                        
Schedule of Equity Method Investments [Line Items]                        
Equity method investment, ownership percentage             11.70% 12.60% 13.50% 13.50% 15.00%  
ViiV Healthcare Limited [Member] | Shionogi & Co., Ltd. [Member]                        
Schedule of Equity Method Investments [Line Items]                        
Equity method investment, ownership percentage                   10.00%    
ViiV Healthcare Limited [Member] | Other Nonoperating Income (Expense) [Member]                        
Schedule of Equity Method Investments [Line Items]                        
Gain (loss) in increase (reduction) of interest in subsidiary or equity method investment         (30.0) (32.0)            
Gain (loss) in increase (reduction) of interest in subsidiary or equity method investment           (32.0)            
Shionogi-Viiv Healthcare LLC [Member]                        
Schedule of Equity Method Investments [Line Items]                        
Percentage of voting interests acquired                   50.00%    
Laboratorio Teuto Brasilero [Member]                        
Schedule of Equity Method Investments [Line Items]                        
Equity method investment, ownership percentage       40.00%                
Equity method investment, recognized gain (loss)           (223.0)            
Equity method investment, other than temporary impairment         56.0 32.0            
Laboratorio Teuto Brasilero [Member] | Laboratorio Teuto Brasilero [Member]                        
Schedule of Equity Method Investments [Line Items]                        
Noncontrolling interest, ownership percentage by parent       60.00%                
Laboratorio Teuto Brasilero [Member] | Other Nonoperating Income (Expense) [Member]                        
Schedule of Equity Method Investments [Line Items]                        
Equity method investment, recognized gain (loss)         55.0 (223.0)            
Equity method investment, other than temporary impairment         $ 56.0 $ 32.0            
AM Pharma BV [Member]                        
Schedule of Equity Method Investments [Line Items]                        
Cost method investment, contingent payments, maximum exposure $ 512.5                      
Discounted Cash Flows Technique [Member] | Hisun Pfizer Pharmaceuticals Co. Ltd [Member]                        
Schedule of Equity Method Investments [Line Items]                        
Fair value inputs, discount rate       12.00%   11.50%            
Long-term Investments [Member] | AM Pharma BV [Member]                        
Schedule of Equity Method Investments [Line Items]                        
Cost method investment, upfront and milestone payments $ 87.5                      
[1] Amounts may not add due to rounding.
[2] In 2013, represents the gain associated with the transfer of certain product rights to Hisun Pfizer. For additional information, see Note 2E.